Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Burmester

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Annals of the Rheumatic Diseases|August 31, 2007
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapyD van der Heijde, G Burmester, J Melo-Gomes, et al.
Bone Marrow Transplantation|April 25, 2001
Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathyO Rosen, G Massenkeil, F Hiepe, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of responseJ Braun, X Baraliakos, J Listing, et al.
Annals of the Rheumatic Diseases|August 23, 2008
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapyD van der Heijde, G Burmester, J Melo-Gomes, et al.
Annals of the Rheumatic Diseases|September 25, 2004
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitisJ Braun, J Brandt, J Listing, et al.
Rheumatology (Oxford, England)|March 11, 2005
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 yearsJ Braun, X Baraliakos, J Brandt, et al.
Arthritis and Rheumatism|August 9, 2003
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trialJ Braun, J Brandt, J Listing, et al.
Annals of the Rheumatic Diseases|December 5, 2008
Effects of Porphyromonas gingivalis on cell cycle progression and apoptosis of primary human chondrocytesN Pischon, E Röhner, A Hocke, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
RMD Open|August 6, 2016
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reductionX Baraliakos, F Heldmann, F van den Bosch, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Annals of the Rheumatic Diseases|August 31, 2007
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapyD van der Heijde, G Burmester, J Melo-Gomes, et al.
Bone Marrow Transplantation|April 25, 2001
Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathyO Rosen, G Massenkeil, F Hiepe, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of responseJ Braun, X Baraliakos, J Listing, et al.
Annals of the Rheumatic Diseases|August 23, 2008
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapyD van der Heijde, G Burmester, J Melo-Gomes, et al.
Annals of the Rheumatic Diseases|September 25, 2004
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitisJ Braun, J Brandt, J Listing, et al.
Rheumatology (Oxford, England)|March 11, 2005
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 yearsJ Braun, X Baraliakos, J Brandt, et al.
Arthritis and Rheumatism|August 9, 2003
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trialJ Braun, J Brandt, J Listing, et al.
Annals of the Rheumatic Diseases|December 5, 2008
Effects of Porphyromonas gingivalis on cell cycle progression and apoptosis of primary human chondrocytesN Pischon, E Röhner, A Hocke, et al.
Annals of the Rheumatic Diseases|January 28, 2006
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearA Kavanaugh, C E Antoni, D Gladman, et al.
RMD Open|August 6, 2016
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reductionX Baraliakos, F Heldmann, F van den Bosch, et al.
Pageof 7